Health-related quality of life in patients with glioblastoma: a randomised controlled trial

Détails

ID Serval
serval:BIB_F8ABF8674D96
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Health-related quality of life in patients with glioblastoma: a randomised controlled trial
Périodique
Lancet Oncology
Auteur(s)
Taphoorn  M. J., Stupp  R., Coens  C., Osoba  D., Kortmann  R., van den Bent  M. J., Mason  W., Mirimanoff  R. O., Baumert  B. G., Eisenhauer  E., Forsyth  P., Bottomley  A.
ISSN
1470-2045 (Print)
Statut éditorial
Publié
Date de publication
12/2005
Volume
6
Numéro
12
Pages
937-44
Notes
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Dec
Résumé
BACKGROUND: A randomised controlled trial of radiotherapy alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma showed that survival was higher for patients assigned combination treatment compared with those assigned standard radiotherapy alone. This paper reports the health-related quality of life (HRQOL) of the patients in this trial. METHODS: 573 patients with newly diagnosed glioblastoma were randomly allocated either radiotherapy alone or radiotherapy and temozolomide. The primary endpoint was survival, and HRQOL was a secondary endpoint. We assessed HRQOL at baseline and at every 3 months during treatment until progression using the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) and the EORTC brain cancer module (EORTC BN-20). We calculated changes from baseline score for seven predefined HRQOL measures (fatigue, overall health, social function, emotional function, future uncertainty, insomnia, and communication deficit) and differences between groups for these measures at every time point. The significance of, and proportions of patients with, improved HRQOL scores--defined as a change of 10 points or more--were recorded. This trial is registered on the US National Cancer Institute website http://www.cancer.gov/search/NewClinicalTrials, NCT00006353. FINDINGS: Baseline questionnaires were available for 490 (86%) patients. Baseline HRQOL scores did not differ between groups. At first follow-up, groups differed only in social functioning, favouring the radiotherapy-only group (mean score 79.0 [SD 3.2] for patients assigned radiotherapy vs 67.4 [2.7] for those assigned radiotherapy and temozolomide; difference between groups 11.6 points [95% CI 3.5-19.7], p=0.0052). Over subsequent assessments, HRQOL was much the same between treatment groups. INTERPRETATION: Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL.
Mots-clé
Activities of Daily Living Adolescent Adult Aged Antineoplastic Agents, Alkylating/*therapeutic use Brain Neoplasms/*complications/drug therapy/*radiotherapy Combined Modality Therapy Dacarbazine/*analogs & derivatives/therapeutic use Emotions Fatigue Female Health Status Humans Male Middle Aged *Quality of Life Social Behavior Stress, Psychological Treatment Outcome
Pubmed
Web of science
Création de la notice
28/01/2008 9:39
Dernière modification de la notice
03/03/2018 22:52
Données d'usage